Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Demeter Biotech (also known as Demot Biotechnology) is an innovative synthetic biology company specializing in the development of microalgae-based biomanufacturing platforms. Headquartered in Zhuhai, China, and founded by Dr. Danxiang Han, the company utilizes its proprietary "Light Carbon Intelligent Manufacturing" platform to engineer microalgae cell factories optimized for the sustainable production of high-value bioactive compounds. Its product portfolio includes natural carotenoids such as fucoxanthin and astaxanthin, functional lipids like EPA (Omega-3), and specialized proteins for the human health, nutrition, and cosmetic industries. Backed by prominent investors including Sequoia China, Demeter Biotech aims to provide carbon-neutral, high-purity alternatives to traditional chemical synthesis and resource-intensive extraction methods.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Demeter Biotech.